NUTX vs. AUGX, LIAN, PLUR, RPID, CODX, AKLI, GBS, AWH, BCLI, and MRKR
Should you be buying Nutex Health stock or one of its competitors? The main competitors of Nutex Health include Augmedix (AUGX), LianBio (LIAN), Pluri (PLUR), Rapid Micro Biosystems (RPID), Co-Diagnostics (CODX), Akili (AKLI), GBS (GBS), Aspira Women's Health (AWH), Brainstorm Cell Therapeutics (BCLI), and Marker Therapeutics (MRKR). These companies are all part of the "medical" sector.
Augmedix (NASDAQ:AUGX) and Nutex Health (NASDAQ:NUTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk.
Nutex Health received 2 more outperform votes than Augmedix when rated by MarketBeat users. Likewise, 100.00% of users gave Nutex Health an outperform vote while only 50.00% of users gave Augmedix an outperform vote.
Augmedix has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, Nutex Health has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500.
In the previous week, Augmedix had 20 more articles in the media than Nutex Health. MarketBeat recorded 23 mentions for Augmedix and 3 mentions for Nutex Health. Augmedix's average media sentiment score of 0.27 beat Nutex Health's score of 0.14 indicating that Nutex Health is being referred to more favorably in the news media.
87.1% of Augmedix shares are held by institutional investors. Comparatively, 5.3% of Nutex Health shares are held by institutional investors. 11.0% of Augmedix shares are held by insiders. Comparatively, 38.5% of Nutex Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Augmedix has higher earnings, but lower revenue than Nutex Health. Augmedix is trading at a lower price-to-earnings ratio than Nutex Health, indicating that it is currently the more affordable of the two stocks.
Nutex Health has a net margin of -15.85% compared to Nutex Health's net margin of -41.95%. Augmedix's return on equity of -44.06% beat Nutex Health's return on equity.
Augmedix presently has a consensus target price of $3.88, indicating a potential upside of 215.04%. Nutex Health has a consensus target price of $15.00, indicating a potential upside of 1,936.11%. Given Augmedix's stronger consensus rating and higher possible upside, analysts clearly believe Nutex Health is more favorable than Augmedix.
Summary
Nutex Health beats Augmedix on 12 of the 18 factors compared between the two stocks.
Get Nutex Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nutex Health Competitors List
Related Companies and Tools
